Soleno Therapeutics VYKAT XR data strengthens long-term case in Prader-Willi syndrome
Find out how Soleno Therapeutics’ VYKAT XR data could reshape hyperphagia treatment in Prader-Willi syndrome.
Pharma & Biotech
Pharma & Biotech
Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.